The Multiple Myeloma Channel is supported with funding from BMS (Gold) and Legend Biotech (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2019 | VenBd in R/R MM: updated analysis of BELLINI
Philippe Moreau, MD, University Hospital Hôtel-Dieu, Nantes, France, outlines the updated efficacy and safety results of venetoclax in combination with bortezomib and dexamethasone (VenBd) in relapsed/refractory multiple myeloma (MM) from the BELINNI trial (NCT02755597). Prof. Moreau highlights the favorable benefit of venetoclax, particularly in patients with t(11:14) or high expression of BCL-2. This interview took place at the American Society of Hematology (ASH) 2019 Annual Meeting and Exposition in Orlando, FL.
